{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:43:50Z","timestamp":1790775830672,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vitae"},{"name":"Glenmark"},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Asana"},{"name":"Innovaderm"},{"name":"Dermira"},{"DOI":"10.13039\/100011944","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kadmon"},{"name":"Dermira"},{"DOI":"10.13039\/100001003","name":"Boehringer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovaderm"},{"name":"Kyowa"},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Serono"},{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Delenex"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004702","name":"Baxter","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paraxel"},{"name":"Xenoport"},{"name":"Kineta"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jaci.2018.11.031","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T11:41:08Z","timestamp":1545133268000},"page":"2095-2107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases"],"prefix":"10.1016","volume":"143","author":[{"given":"Tali","family":"Czarnowicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Kameyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeriel","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei-Chi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace W.","family":"Kimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Chima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2018.11.031_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0749.2006.00355.x","article-title":"The definition and assessment of vitiligo: a\u00a0consensus report of the Vitiligo European Task Force","volume":"20","author":"Taieb","year":"2007","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.jaci.2018.11.031_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/archderm.1977.01640010049006","article-title":"Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark","volume":"113","author":"Howitz","year":"1977","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib3","first-page":"160","article-title":"Clinical practice. Vitiligo","volume":"360","author":"Taieb","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2018.11.031_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"New discoveries in the pathogenesis and classification of vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaci.2017.07.011","article-title":"Vitiligo: mechanistic insights lead to novel treatments","volume":"140","author":"Frisoli","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaad.2016.11.010","article-title":"Current and emerging treatments for vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib7","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jaad.2018.02.023","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B","volume":"78","author":"Joshipura","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib10","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2018.11.031_bib11","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/pcmr.12219","article-title":"Type I interferon signature in the initiation of the immune response in vitiligo","volume":"27","author":"Bertolotti","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2018.11.031_bib12","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/bjd.14416","article-title":"Increased\u00a0expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo","volume":"174","author":"Wang","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci Transl Med"},{"issue":"suppl","key":"10.1016\/j.jaci.2018.11.031_bib14","first-page":"S16","article-title":"The role of the Th1 chemokine CXCL10 in vitiligo","volume":"3","author":"Antonelli","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jaci.2018.11.031_bib15","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib16","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/pcmr.12284","article-title":"Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation","volume":"27","author":"Eby","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2018.11.031_bib17","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1096\/fj.201701242RR","article-title":"IL-17 induces cellular stress microenvironment of melanocytes to promote autophagic cell apoptosis in vitiligo","volume":"32","author":"Zhou","year":"2018","journal-title":"FASEB J"},{"key":"10.1016\/j.jaci.2018.11.031_bib18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/pcmr.12355","article-title":"Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development","volume":"28","author":"Zhou","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2018.11.031_bib19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2230.2010.03972.x","article-title":"Role of interleukin-17 in the pathogenesis of vitiligo","volume":"36","author":"Bassiouny","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib20","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jaad.2011.07.018","article-title":"Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-beta) in patients with vitiligo","volume":"66","author":"Khan","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.autrev.2016.01.004","article-title":"The role of IL-17 in vitiligo: a review","volume":"15","author":"Singh","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2018.11.031_bib22","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1684\/ejd.2013.2023","article-title":"Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: a case-controlled study on eighty-four patients","volume":"23","author":"Elela","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/01.LAB.0000069521.42488.1B","article-title":"Immunopolarization of CD4(+) and CD8(+) T cells to type-1-like is associated with melanocyte loss in human vitiligo","volume":"83","author":"Wankowicz-Kalinska","year":"2003","journal-title":"Lab Invest"},{"key":"10.1016\/j.jaci.2018.11.031_bib24","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T\u00a0cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2133.2001.03952.x","article-title":"Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo","volume":"144","author":"Jimbow","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib26","doi-asserted-by":"crossref","first-page":"e18907","DOI":"10.1371\/journal.pone.0018907","article-title":"Th17 cells and activated dendritic cells are increased in vitiligo lesions","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2018.11.031_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/pcmr.12190","article-title":"IFN-gamma inhibits basal and\u00a0alpha-MSH-induced melanogenesis","volume":"27","author":"Son","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2018.11.031_bib28","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1073\/pnas.1304988111","article-title":"IFN-gamma signaling maintains skin pigmentation homeostasis through regulation of melanosome maturation","volume":"111","author":"Natarajan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2018.11.031_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1755-148X.2011.00945.x","article-title":"Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris","volume":"25","author":"Kotobuki","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2018.11.031_bib30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/exd.12369","article-title":"T helper 17 and Tregs: a novel proposed mechanism for NB-UVB in vitiligo","volume":"23","author":"Hegazy","year":"2014","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib32","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2018.11.031_bib33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2015.01.020","article-title":"Severe\u00a0atopic dermatitis is characterized by selective expansion of circulating TH2\/TC2 and TH22\/TC22, but not TH17\/TC17, cells within the skin-homing T-cell population","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/all.13080","article-title":"Circulating CLA+\u00a0T\u00a0cells in atopic dermatitis and their possible role as peripheral biomarkers","volume":"72","author":"Czarnowicki","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.11.031_bib35","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/labinvest.3780138","article-title":"Local immune response in skin of generalized vitiligo patients\u2014destruction of melanocytes is associated with the prominent presence of CLA(+) T cells at the perilesional site","volume":"80","author":"van den Wijngaard","year":"2000","journal-title":"Lab Invest"},{"key":"10.1016\/j.jaci.2018.11.031_bib36","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000250627","article-title":"Coincidence of vitiligo, alopecia areata, onychodystrophy, localized scleroderma and lichen planus","volume":"159","author":"Brenner","year":"1979","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaci.2018.11.031_bib37","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","article-title":"Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis","volume":"151","author":"Mohan","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib38","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/jamadermatol.2013.4228","article-title":"Association between vitiligo and atopic disorders: a pilot study","volume":"149","author":"Silverberg","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaci.2015.03.032","article-title":"Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib40","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/all.13346","article-title":"Alopecia\u00a0areata is characterized by expansion of circulating Th2\/Tc2\/Th22, within the skin-homing and systemic T-cell populations","volume":"73","author":"Czarnowicki","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.11.031_bib41","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/archderm.140.6.677","article-title":"Parametric modeling of UV-B of narrowband phototherapy for vitiligo using a novel quantitative tool\u2014the vitiligo area scoring index","volume":"140","author":"Hamzavi","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib42","doi-asserted-by":"crossref","first-page":"750342","DOI":"10.1155\/2011\/750342","article-title":"Disease severity indexes and treatment evaluation criteria in vitiligo","volume":"2011","author":"Kawakami","year":"2011","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.jaci.2018.11.031_bib43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.13432","article-title":"Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo","volume":"172","author":"Komen","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib44","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T\u00a0cell subsets: function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib45","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2018.11.031_bib46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0923-1811(01)00174-8","article-title":"Flow cytometric analysis of IL-4, IL-13 and IFN-gamma expression in peripheral blood mononuclear cells and detection of circulating IL-13 in patients with atopic dermatitis provide evidence for the involvement of type 2 cytokines in the disease","volume":"29","author":"Kaminishi","year":"2002","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2018.11.031_bib47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/09546634.2013.879093","article-title":"The role of IL-17 in psoriasis","volume":"26","author":"Malakouti","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaci.2018.11.031_bib48","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/ced.12845","article-title":"Circulating T-helper 17 cells and associated cytokines in psoriasis","volume":"41","author":"Chhabra","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib49","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.4049\/jimmunol.1003224","article-title":"CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game","volume":"187","author":"Long","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib50","first-page":"1053","article-title":"A unique phenotype of skin-associated lymphocytes in humans\u2014preferential expression of the Heca-452 epitope by benign and malignant T-cells at cutaneous sites","volume":"136","author":"Picker","year":"1990","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2018.11.031_bib51","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri2496","article-title":"Migration, maintenance and recall of memory T\u00a0cells in peripheral tissues","volume":"9","author":"Woodland","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib52","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaci.2015.05.049","article-title":"Early\u00a0pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen\u00a0(CLA)(+) TH2\/TH1 cell imbalance, whereas adults acquire CLA(+) TH22\/TC22 cell subsets","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib53","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2340\/00015555-2080","article-title":"Interferon-gamma Inhibits melanogenesis and induces apoptosis in melanocytes: a pivotal role of CD8+ cytotoxic T lymphocytes in vitiligo","volume":"95","author":"Yang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2018.11.031_bib54","first-page":"643","article-title":"IFN-gamma in vitiligo, is it the fuel or the fire?","volume":"95","author":"Harris","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2018.11.031_bib55","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib56","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/jid.2012.331","article-title":"IL-4 inhibits the melanogenesis of normal human melanocytes through the JAK2-STAT6 signaling pathway","volume":"133","author":"Choi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib57","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/1346-8138.12746","article-title":"Leukoderma in patients with atopic dermatitis","volume":"42","author":"Kuriyama","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib58","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/all.13128","article-title":"Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses' Health Study 2","volume":"72","author":"Drucker","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.11.031_bib59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/cei.12198","article-title":"Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis","volume":"175","author":"Ma","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib60","doi-asserted-by":"crossref","first-page":"e51752","DOI":"10.1371\/journal.pone.0051752","article-title":"Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis","volume":"8","author":"Singh","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2018.11.031_bib61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.humimm.2016.12.010","article-title":"Th9 cells and IL-9 in autoimmune disorders: pathogenesis and therapeutic potentials","volume":"78","author":"Deng","year":"2017","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib62","doi-asserted-by":"crossref","first-page":"71001","DOI":"10.18632\/oncotarget.11681","article-title":"TH9 cell differentiation, transcriptional control and function in inflammation, autoimmune diseases and cancer","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaci.2018.11.031_bib63","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaad.2008.09.048","article-title":"The role of helper and regulatory T cells in the pathogenesis of vitiligo","volume":"60","author":"Basak","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib64","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.34477","article-title":"Brief report: inhibition of interleukin-6 function corrects Th17\/Treg cell imbalance in patients with rheumatoid arthritis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2018.11.031_bib65","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00296-011-1984-x","article-title":"Disturbed Th17\/Treg balance in patients with rheumatoid arthritis","volume":"32","author":"Niu","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jaci.2018.11.031_bib66","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00005-015-0344-z","article-title":"The role of IL-17 and Th17 lymphocytes in autoimmune diseases","volume":"63","author":"Tabarkiewicz","year":"2015","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.jaci.2018.11.031_bib67","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cytogfr.2012.07.002","article-title":"Emerging role of interleukin-22 in autoimmune diseases","volume":"24","author":"Pan","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jaci.2018.11.031_bib68","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib69","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00109-009-0457-0","article-title":"IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not","volume":"87","author":"Wolk","year":"2009","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.jaci.2018.11.031_bib70","doi-asserted-by":"crossref","first-page":"109161","DOI":"10.18632\/oncotarget.22644","article-title":"Interleukin-22 participates in the inflammatory process of vitiligo","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaci.2018.11.031_bib71","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jocd.12517","article-title":"Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-alpha) in vitiligo-New insight into pathogenesis of disease","volume":"18","author":"Sushama","year":"2019","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib72","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/jid.2014.527","article-title":"Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a\u00a0randomized, double blind, placebo-controlled study","volume":"135","author":"Cavalie","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib73","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35051113","article-title":"ICOS is essential for effective T-helper-cell responses","volume":"409","author":"Tafuri","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2018.11.031_bib74","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.4049\/jimmunol.181.2.1019","article-title":"ICOS costimulation expands Th2 immunity by augmenting migration of lymphocytes to draining lymph nodes","volume":"181","author":"Tesciuba","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib75","doi-asserted-by":"crossref","first-page":"55ra78","DOI":"10.1126\/scitranslmed.3000448","article-title":"The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells","volume":"2","author":"Paulos","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2018.11.031_bib76","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clim.2005.02.010","article-title":"Regulation of immune and autoimmune responses by ICOS-B7h interaction","volume":"115","author":"Nurieva","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib77","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0896-8411(03)00119-7","article-title":"Regulation of immune and autoimmune responses by ICOS","volume":"21","author":"Dong","year":"2003","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaci.2018.11.031_bib78","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4049\/jimmunol.1502241","article-title":"Loss of immune tolerance is controlled by ICOS in Sle1 mice","volume":"197","author":"Mittereder","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib79","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaci.2010.05.022","article-title":"Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17\/TH1 and regulatory T cells","volume":"126","author":"Vocanson","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib80","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.4049\/jimmunol.1401082","article-title":"The inducible costimulator augments Tc17 cell responses to self and tumor tissue","volume":"194","author":"Nelson","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib81","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/pcmr.12105","article-title":"Decreased regulatory T-cells and CD4(+)\/CD8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo","volume":"26","author":"Dwivedi","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2018.11.031_bib82","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1471-4906(00)01844-5","article-title":"A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo","volume":"22","author":"Das","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib83","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coi.2016.09.008","article-title":"Understanding mechanisms of autoimmunity through translational research in vitiligo","volume":"43","author":"Strassner","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib84","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1067\/mai.2002.129339","article-title":"The role of suppressor T cells in regulation of immune responses","volume":"110","author":"McHugh","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.11.031_bib85","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fgene.2016.00003","article-title":"Genetic susceptibility to vitiligo: GWAS approaches for identifying vitiligo susceptibility genes and loci","volume":"7","author":"Shen","year":"2016","journal-title":"Front Genet"},{"key":"10.1016\/j.jaci.2018.11.031_bib86","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1755-148X.2010.00688.x","article-title":"Reduced skin homing by functional Treg in vitiligo","volume":"23","author":"Klarquist","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2018.11.031_bib87","doi-asserted-by":"crossref","first-page":"145409","DOI":"10.1155\/2015\/145409","article-title":"Decreased circulating T regulatory cells in Egyptian patients with nonsegmental vitiligo: correlation with disease activity","volume":"2015","author":"Hegab","year":"2015","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.jaci.2018.11.031_bib88","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjd.13511","article-title":"Alteration in regulatory T cells and programmed cell death 1-expressing regulatory T cells in active generalized vitiligo and their clinical correlation","volume":"172","author":"Tembhre","year":"2015","journal-title":"Br\u00a0J Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib89","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1684\/ejd.2014.2436","article-title":"Regulatory T cells from active non-segmental vitiligo exhibit lower suppressive ability on CD8+CLA+ T cells","volume":"24","author":"Lin","year":"2014","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib90","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jaad.2005.03.032","article-title":"Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo","volume":"53","author":"Kakourou","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.11.031_bib91","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MOP.0000000000000375","article-title":"Understanding autoimmunity of vitiligo and alopecia areata","volume":"28","author":"Rork","year":"2016","journal-title":"Curr Opin Pediatr"},{"issue":"suppl","key":"10.1016\/j.jaci.2018.11.031_bib92","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jisp.2016.10.023","article-title":"Replenishing regulatory T cells to halt depigmentation in vitiligo","volume":"18","author":"Le Poole","year":"2017","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jaci.2018.11.031_bib93","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/s41598-018-19407-w","article-title":"PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin","volume":"8","author":"Miao","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2018.11.031_bib94","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/exd.12264","article-title":"Vitiligo and alopecia areata: apples and oranges?","volume":"22","author":"Harris","year":"2013","journal-title":"Exp Dermatol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674918327295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674918327295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:20:22Z","timestamp":1758792022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674918327295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0091674918327295"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2018.11.031","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2018.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}